NCT00357708View on ClinicalTrials.gov

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2009

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Chronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm, UnclassifiablePhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRelapsing Chronic Myelogenous Leukemia
Interventions
DRUG

decitabine

Given IV

DRUG

vorinostat

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00357708 - Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | Biotech Hunter | Biotech Hunter